Novavax Inc(NVAX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 7:40 AM ET (Korea 10/28 20:40)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.52 | Insider Own | 4.97% | Shs Outstand | 164.8M | Perf Week | -12.34% |
| Market Cap | 1.65B | Forward P/E | 122.25 | EPS next Y | 112.1% | Insider Trans | - | Shs Float | 156.8M | Perf Month | -7.22% |
| Enterprise Value | 1.23B | PEG | - | EPS next Q | -0.34 | Inst Own | 65.34% | Short Float | 30.2% | Perf Quarter | 36.51% |
| Income | -0.25B | P/S | 3.99 | EPS this Y | -126.26% | Inst Trans | 0.31% | Short Ratio | 7.67 | Perf Half Y | 26.52% |
| Sales | 0.41B | P/B | - | EPS next 5Y | - | ROA | -21.62% | Short Interest | 47.35M | Perf YTD | 49.11% |
| Book/sh | -1.16 | P/C | 2.3 | EPS past 3/5Y | - | ROE | - | 52W High | -25.14% ($13.39) | Perf Year | 15.17% |
| Cash/sh | 4.36 | P/FCF | - | Sales past 3/5Y | -17.24% 18.76% | ROIC | -241.68% | 52W Low | 61.61% ($6.20) | Perf 3Y | 57.8% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -158.19% | Gross Margin | 78.65% | Volatility(W/M) | 8.17% 10.01% | Perf 5Y | -92.92% |
| Dividend TTM | - | EV/Sales | 2.97 | Sales Y/Y TTM | -61.64% | Oper. Margin | -28.82% | ATR (14) | 0.94 | Perf 10Y | -66.82% |
| Dividend Ex-Date | 2007/12/13 | Quick Ratio | 2.3 | EPS Q/Q | -153.98% | Profit Margin | -59.87% | RSI (14) | 44.07 | Recom | 2.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.33 | Sales Q/Q | -76.3% | SMA20 | -11.05% ($11.26) | Beta | 2.65 | Target Price | $15 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | -3.14% ($10.34) | Rel Volume | 1.1 | Prev Close | $9.4 |
| Employees | 749 | LT Debt/Eq | - | EPS/Sales Surpr. | 15.75% 7.97% | SMA200 | 8.17% ($9.26) | Avg Volume(3M) | 6.18M | Price | $10.02 |
| IPO | 1995/12/5 | Option/Short | Yes/Yes | Trades | 27242 | Volume | 6,774,690 | Change | 6.6% |
💉 Novavax (NVAX) is a U.S. biotech company that has a protein-based vaccine and its own adjuvant (Matrix-M) platform. It commercialized the COVID-19 vaccine Nuvaxovid, and has recently shifted to a lightweight operating model focused on partnerships and licensing, expanding its technology collaborations with multinational pharmaceutical companies.
Over the past 1 year, roughly in the middle
25% below its 1-year high.
Traded about as much as usual. That is 110% of its average volume.
NVAX has a sound balance sheet but weak earning power
Of every $100 in sales, $28.82 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -126.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $399. Peers typically go for $1,261. It is about in line with its own 1-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -92.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
30.2% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #120 of 594 in the industry
Based on market cap of $2B.
FAQ
What kind of company is NVAX?
NVAX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NVAX?
The market cap of NVAX is approximately $1.7B, ranking 2,217 within its sector.
What is the 52-week high and low for NVAX?
NVAX has recorded a 52-week high of $13.39 and a low of $6.20.
